Ftse Mib
34.326,90
0,51%
DAX
18.686,60
1,07%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,27%
Bitcoin
62.630,58
2,36%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE SQZ Biotechnologies Company (SQZ) SQZ Biotechnologies Company (SQZ) Notizie

SQZ

SQZ Biotechnologies (SQZ)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:SQZ
DataOraFonteTitoloSimboloCompagnia
06/05/202412:25GlobeNewswire Inc.Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd WiderNYSE:SQZSQZ Biotechnologies Company
23/01/202422:31Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNYSE:SQZSQZ Biotechnologies Company
22/12/202323:18Edgar (US Regulatory)Form 8-K - Current reportNYSE:SQZSQZ Biotechnologies Company
08/11/202322:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:SQZSQZ Biotechnologies Company
15/06/202322:47Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:SQZSQZ Biotechnologies Company
15/06/202322:38Edgar (US Regulatory)Current Report Filing (8-k)NYSE:SQZSQZ Biotechnologies Company
15/06/202322:30Business WireSQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock SplitNYSE:SQZSQZ Biotechnologies Company
10/05/202322:45Business WireSQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio UpdatesNYSE:SQZSQZ Biotechnologies Company
10/05/202322:35Edgar (US Regulatory)Quarterly Report (10-q)NYSE:SQZSQZ Biotechnologies Company
05/05/202322:32Edgar (US Regulatory)Annual Report to Security Holders (ars)NYSE:SQZSQZ Biotechnologies Company
26/04/202322:32Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NYSE:SQZSQZ Biotechnologies Company
26/04/202322:31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NYSE:SQZSQZ Biotechnologies Company
10/04/202322:32Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NYSE:SQZSQZ Biotechnologies Company
22/03/202321:50Business WireSQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical TrialNYSE:SQZSQZ Biotechnologies Company
22/03/202321:45Business WireSQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio UpdatesNYSE:SQZSQZ Biotechnologies Company
14/02/202320:25Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:SQZSQZ Biotechnologies Company
18/01/202322:30Business WireSQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock ExchangeNYSE:SQZSQZ Biotechnologies Company
06/12/202217:55TipRanksSQZ Biotechnologies (SQZ) Gets a Hold from H.C. WainwrightNYSE:SQZSQZ Biotechnologies Company
06/12/202214:55TipRanksSQZ Biotechnologies (SQZ) Receives a Buy from Brookline Capital MarketsNYSE:SQZSQZ Biotechnologies Company
06/12/202212:45Business WireSQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology CongressNYSE:SQZSQZ Biotechnologies Company
02/12/202212:15TipRanksSQZ Biotechnologies (SQZ) was downgraded to a Hold Rating at H.C. WainwrightNYSE:SQZSQZ Biotechnologies Company
01/12/202213:55TipRanksChardan Capital Sticks to Their Buy Rating for SQZ Biotechnologies (SQZ)NYSE:SQZSQZ Biotechnologies Company
30/11/202222:30Business WireSQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive OfficerNYSE:SQZSQZ Biotechnologies Company
10/11/202215:00Business WireSQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual MeetingNYSE:SQZSQZ Biotechnologies Company
10/11/202212:17TipRanksSQZ Biotechnologies (SQZ) Receives a Buy from H.C. WainwrightNYSE:SQZSQZ Biotechnologies Company
10/11/202201:55TipRanksBrookline Capital Markets Reaffirms Their Buy Rating on SQZ Biotechnologies (SQZ)NYSE:SQZSQZ Biotechnologies Company
09/11/202222:30Business WireSQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio UpdatesNYSE:SQZSQZ Biotechnologies Company
03/10/202212:45Business WireSQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived ImmunotherapyNYSE:SQZSQZ Biotechnologies Company
12/09/202215:15TipRanksBrookline Capital Markets Keeps Their Buy Rating on SQZ Biotechnologies (SQZ)NYSE:SQZSQZ Biotechnologies Company
12/09/202212:00Business WireSQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell TherapiesNYSE:SQZSQZ Biotechnologies Company
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:SQZ

La tua Cronologia

BIT
BPE
Bper Banca
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
NEXI
Nexi S.p.A
BIT
BAMI
Banco BPM
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
FBK
Finecobank
BIT
TIT
Telecom Italia
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network